These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23732905)

  • 21. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Cattepoel S; Hanenberg M; Kulic L; Nitsch RM
    PLoS One; 2011 Apr; 6(4):e18296. PubMed ID: 21483675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An aqueous orally active vaccine targeted against a RAGE/AB complex as a novel therapeutic for Alzheimer's disease.
    Webster SJ; Mruthinti S; Hill WD; Buccafusco JJ; Terry AV
    Neuromolecular Med; 2012 Jun; 14(2):119-30. PubMed ID: 22415896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
    Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
    J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
    Kim HD; Tahara K; Maxwell JA; Lalonde R; Fukuiwa T; Fujihashi K; Van Kampen KR; Kong FK; Tang DC; Fukuchi K
    J Gene Med; 2007 Feb; 9(2):88-98. PubMed ID: 17219449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
    Leverone JF; Spooner ET; Lehman HK; Clements JD; Lemere CA
    Vaccine; 2003 May; 21(17-18):2197-206. PubMed ID: 12706711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer's disease.
    Carrera I; Etcheverría I; Fernández-Novoa L; Lombardi VR; Lakshmana MK; Cacabelos R; Vigo C
    Biomed Res Int; 2015; 2015():807146. PubMed ID: 25759822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternal antibodies facilitate Amyloid-β clearance by activating Fc-receptor-Syk-mediated phagocytosis.
    Illouz T; Nicola R; Ben-Shushan L; Madar R; Biragyn A; Okun E
    Commun Biol; 2021 Mar; 4(1):329. PubMed ID: 33712740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.
    Movsesyan N; Davtyan H; Mkrtichyan M; Petrushina I; Tiraturyan T; Ross T; Agadjanyan MG; Ghochikyan A; Cribbs DH
    Hum Gene Ther; 2010 Nov; 21(11):1569-76. PubMed ID: 20528468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA.
    Hara H; Mouri A; Yonemitsu Y; Nabeshima T; Tabira T
    Vaccine; 2011 Oct; 29(43):7474-82. PubMed ID: 21803105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model.
    Nojima J; Maeda A; Aoki S; Suo S; Yanagihara D; Watanabe Y; Yoshida T; Ishiura S
    Vaccine; 2011 Aug; 29(37):6252-8. PubMed ID: 21726591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
    Paris D; Ganey NJ; Laporte V; Patel NS; Beaulieu-Abdelahad D; Bachmeier C; March A; Ait-Ghezala G; Mullan MJ
    J Neuroinflammation; 2010 Mar; 7():17. PubMed ID: 20211007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.
    Petrushina I; Davtyan H; Hovakimyan A; Davtyan A; Passos GF; Cribbs DH; Ghochikyan A; Agadjanyan MG
    Mol Ther; 2017 Jan; 25(1):153-164. PubMed ID: 28129111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.
    Sigurdsson EM; Knudsen E; Asuni A; Fitzer-Attas C; Sage D; Quartermain D; Goni F; Frangione B; Wisniewski T
    J Neurosci; 2004 Jul; 24(28):6277-82. PubMed ID: 15254082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.
    Ghochikyan A; Mkrtichyan M; Petrushina I; Movsesyan N; Karapetyan A; Cribbs DH; Agadjanyan MG
    Vaccine; 2006 Mar; 24(13):2275-82. PubMed ID: 16368167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease.
    Fu L; Li Y; Hu Y; Zheng Y; Yu B; Zhang H; Wu J; Wu H; Yu X; Kong W
    Sci Rep; 2017 Jan; 7():41041. PubMed ID: 28106117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease.
    Hao YN; Lu QX; Zhai YH; Wang HY; Wu MN; Hu MM; Yang B; Wang ZJ; Wu ZW; Qi JS
    Brain Res Bull; 2018 Oct; 143():116-122. PubMed ID: 30366065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.